Optimising the CAR T cell manufacturing workflow from end to end – Full SpotlightPublished: September 18, 2019
No one can doubt the therapeutic potential and application of CAR-T immunotherapies but it remains a challenge to overcome the inefficiencies and bottlenecks of consistent manufacture of these products. This spotlight discusses some of the ways in which Miltenyi are seeking to optimise the CAR-T manufacturing pathway:
- Maximising data standardisation and reproducability from flow cytometry;
- Progress and challenges in the development of bi-specific CAR-T cell therapies;
- Optimizing cell-based product consistency through automation;
- The expansion of the activated and engineered T cells in culture;
We hear from leading Miltenyi experts and academic collaborators as they discuss the ongoing challenges in CAR-T manufacture, and the innovative ways in which they seek to overcome them.
You can download the full Spotlight on Optimising the CAR T cell manufacturing workflow from end to end free of charge – simply login or register here to become a member